Aferrix

Company Overview

Snapshot

Founded in February 2002 by Ioav Cabantchik, Aferrix operated with 1–10 employees. The company focused on developing diagnostic tools for iron toxicity, and its products were CE marked for IVD use.

Business overview

Aferrix developed diagnostic tools for the early detection and monitoring of serum iron toxicity, offering solutions that quantified toxic iron forms not identified by conventional tests. The company provided iron testing services and kits, primarily serving research and treatment centers specializing in iron overload diseases such as thalassemia, hemochromatosis, and myelodysplastic syndrome. Additionally, Aferrix supported pharmaceutical companies in the development of iron chelators, operating within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Aferrix's primary focus?

Aferrix specializes in developing diagnostic tools for the early diagnosis and monitoring of serum iron toxicity in body fluids.

Which markets does Aferrix serve?

Aferrix serves research and treatment centers specializing in iron overload diseases, as well as pharmaceutical companies developing iron chelators.

What is the status of Aferrix's products?

All of Aferrix's products are CE marked for IVD (In Vitro Diagnostic) use.

When was Aferrix founded?

Aferrix was founded in February 2002.

What is the operational status of Aferrix?

Aferrix ceased to operate in January 2023.